Pulmonary hypertension in hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease): A 10-year follow-up;Pulmonale hypertonie bei hereditärer hämorrhagischer teleangiektasie (Morbus Osler): Verlauf über 10 jahre

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 23, 2005, Pages 1434-1437

  Schlag, K ^a   Opitz, C ^b   Wensel, R ^c   Felix, S ^a   Ewert, Ralf ^a,d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b German Red Cross Hospital   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Bereich Pneumologie Infektiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PROSTANOID;

ADULT; ANAMNESIS; ARTICLE; BLEEDING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDICATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART SOUND; HUMAN; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; SYMPTOMATOLOGY;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; EPISTAXIS; EPOPROSTENOL; FEMALE; FUROSEMIDE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MIDDLE AGED; NIFEDIPINE; PEDIGREE; PHENPROCOUMON; PYRIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT FAILURE; VASODILATOR AGENTS;

EID: 20844435996     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870835     Document Type: Article

References (14)

1. Abdalla SA, Gallione CJ, Barst RJ et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004; 23: 373-377
2. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123
3. Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169: 994-1000
4. Habedank D, Reindl I, Vietzke G et al. Ventilatory efficiency and exercise tolerance in 101 healthy volunteers. Eur J Appl Physiol Occup Physiol 1998; 77: 421-426 .
5. Nagaya N, Uematsu M, Okano Y et al. Effect of orally active prostacyclin analoque on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188-1192
6. Ocran K, Förster U, Haake K, Wermke W. Hereditäre hämorrhagische Teleangiektasie (Morbus Osler-Weber-Rendu). Dtsch Med Wochenschr 2003; 128: 2593-2597
7. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824
8. Pasche B, Wollstein AC, Zoll B, Folz B. Rendu-Osler-Weber-Syndrom. Dtsch Ärztebl 2003; 100: A490-493
9. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729
10. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (Suppl 12); 5S-12S
11. Trell E, Johansson BW, Linell F, Ripa J. Familial pulmonary hypertension and multiple abnormalities of large systemic arteries in Osler's disease. Am J Med 1972; 53: 50-63
12. Trembath RC. Mutations in the TGF-beta type receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasiea, implies pathyway specificity. J Heart Lung Transplant 2001; 20: 175
13. Van den Driesche S, Mummery CL, Westermann CJJ. Hereditary hemorrhagic teleangiectasia: an update on transforming growth factor β signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003; 58: 20-31
14. Vogel M, Berger F, Dähnert I, Bauer U, Lange PE. Untersuchung der Wirkung von Cicletanin (oraler Stimulator der Prostacyclinsynthese) in der Behandlung des sekundären pulmonalen Hochdrucks. Z Kardiol 1998; 87 (Suppl 1); 241